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Background: Both sodium bicarbonate and N-acetylcysteine (NAC) have been proposed as therapies for the prevention of contrast induced 
nephropathy (CIN). However, despite multiple publications there remains considerable uncertainty regarding the efficacy of either therapy.
Methods: A systematic review was performed to identify randomized trials using sodium bicarbonate or NAC for the prevention of CIN. Since trial 
size has been previously shown to account for much of the heterogeneity in this literature, studies were categorized as either large (>290 subjects) 
or small in the analysis. 290 patients would be required to show that the CIN rate using either therapy could be reduced from 15% to 5%.
Results: 53 trials were identified. There were 37 trials in which NAC was investigated. Only three NAC trial were defined as large. Among the large 
trials, there was a significant benefit for NAC in only one study; in the other two large trials there was no statistically significant difference with 
the treatment effect (P=0.63 and P=0.79). Among the 34 small NAC trials, there was a statistically significant benefit for N-acetylcysteine use 
(odds ratio, 0.73; 95% CI, 0.54-0.99). However, in 16 of the small NAC trials, the point estimate favored control and in 18 it favored NAC use. 
In both large and small trials there remained evidence of heterogeneity that was statistically significant, P = 0.002 and P = 0.014, respectively. 
There were 19 sodium bicarbonate trials identified of which four were defined as large. Among the large trials, there was no evidence of benefit for 
sodium bicarbonate hydration (RR, 0.94; 95% CI, 0.71-1.25). A marginal treatment benefit was observed in the 15 small trials (RR, 0.67; 95% CI, 
0.44-1.01). In the sodium bicarbonate trials there was no evidence of heterogeneity in the large trials (P = 0.40); however, there was significant 
heterogeneity in small trials (P = 0.036).
Conclusions: In aggregate, 53 trials of sodium bicarbonate and NAC were identified. Of these, only seven were defined as large and only one of the 
large trials was statistically significant in favor of N-acetylcysteine. Therefore, it is likely that neither therapy is effective for the prevention of contrast 
induced nephropathy.
